Table 1. Patient demographic and tumor characteristics per chemotherapy regimens prior to bevacizumab.

Variable		<3 Prior regimens (n=29)	≥3 Prior regimens (n=31)	p-value
Race				0.63
	White	22 (75.86)	26 (83.87)
	Black	3 (10.34)	1 (3.23)
	Hispanic	2 (6.9)	2 (6.45)
	American-Indian	0	1 (3.23)
	Unknown	2 (6.9)	1 (3.23)
Age at start of bevacizumab (yr)		57 (37–83)	60 (35–79)	0.98
BMI at bevacizumab start (kg/m2)		26.56 (16.65–39.39)	24.67 (18.61–42.58)	0.85
Stage				0.36
	IA–IIIC	1 (3.44)	2 (6.5)
	IIA–IV	28 (96.6)	29 (93.5)
Histology				0.50
	Serous	20 (68.97)	18 (58.1)
	Adenocarcinoma	8 (27.59)	10 (32.26)
	Clear cell, mixed	1 (3.44)	3 (9.68)
Debulking				0.51
	Optimal	18 (62.07)	22 (70.97)
Platinum resistant				0.99
	Yes	15 (51.72)	16 (51.61)
Prior radiation to abdominopelvic area				0.93
	Yes	3 (10.34)	3 (9.68)
Prior bowel surgery				0.61
	Yes	14 (48.28)	17 (54.84)
Time from bowel surgery to start of bevacizumab (mo)		23.11 (8.17–41.6)	45.93 (21.2–103.07)	<0.001
Bevacizumab combined with cytotoxic chemotherapy				0.24
	Yes	21 (72.41)	18 (58.06)
Number of prior cytotoxic regimens		2 (2)	3 (3-9)	<0.001
Number of bevacizumab doses		9 (3–45)	10 (2–33)	0.97
Cumulative bevacizumab received (mg)		8,800 (1,440–81,525)	10,000 (1,710–36,300)	0.63
Follow-up after last dose of bevacizumab (mo)		11.3 (1.47–60.4)	10.73 (0.27–51.3)	0.60

Values are presented as number (%) or median (range).

BMI, body mass index.